Optimized microfluidic formulation and organic excipients for improved lipid nanoparticle mediated genome editing,Lab on a Chip

当前位置： X-MOL 学术 › Lab Chip › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Optimized microfluidic formulation and organic excipients for improved lipid nanoparticle mediated genome editing
Lab on a Chip ( IF 6.1 ) Pub Date : 2024-07-22 , DOI: 10.1039/d4lc00283k
Rohan Palanki _{1,

2} , Emily L Han ₁ , Amanda M Murray ₁ , Rohin Maganti _{1,

2} , Sophia Tang ₁ , Kelsey L Swingle ₁ , Dongyoon Kim ₁ , Hannah Yamagata ₁ , Hannah C Safford ₁ , Kaitlin Mrksich ₁ , William H Peranteau ₂ , Michael J Mitchell _{1,

3,

4,

5,

6,

7,

8}

Affiliation

mRNA-based gene editing platforms have tremendous promise in the treatment of genetic diseases. However, for this potential to be realized in vivo, these nucleic acid cargos must be delivered safely and effectively to cells of interest. Ionizable lipid nanoparticles (LNPs), the most clinically advanced non-viral RNA delivery system, have been well-studied for the delivery of mRNA but have not been systematically optimized for the delivery of mRNA-based CRISPR-Cas9 platforms. In this study, we investigated the effect of microfluidic and lipid excipient parameters on LNP gene editing efficacy. Through in vitro screening in liver cells, we discovered distinct trends in delivery based on phospholipid, cholesterol, and lipid-PEG structure in LNP formulations. Combination of top-performing lipid excipients produced an LNP formulation that resulted in 3-fold greater gene editing in vitro and facilitated 3-fold greater reduction of a therapeutically-relevant protein in vivo relative to the unoptimized LNP formulation. Thus, systematic optimization of LNP formulation parameters revealed a novel LNP formulation that has strong potential for delivery of gene editors to the liver to treat metabolic disease.

中文翻译：

优化的微流控制剂和有机辅料，用于改进脂质纳米颗粒介导的基因组编辑

基于 mRNA 的基因编辑平台在治疗遗传疾病方面具有巨大的前景。然而，为了在体内实现这种潜力，这些核酸转运物必须安全有效地递送到感兴趣的细胞。可电离脂质纳米颗粒（LNP）是临床上最先进的非病毒 RNA 递送系统，已对 mRNA 的递送进行了充分研究，但尚未针对基于 mRNA 的 CRISPR-Cas9 平台的递送进行系统优化。在这项研究中，我们研究了微流控和脂质辅料参数对 LNP 基因编辑功效的影响。通过在肝细胞中进行体外筛选，我们发现了 LNP 制剂中基于磷脂、胆固醇和脂质-PEG 结构的递送的不同趋势。与未优化的 LNP 制剂相比，性能最佳的脂质辅料组合产生了 LNP 制剂，该制剂在体外的基因编辑作用提高了 3 倍，并促进了治疗相关蛋白在体内的减少量提高 3 倍。因此，LNP 制剂参数的系统优化揭示了一种新型 LNP 制剂，该制剂具有将基因编辑器递送到肝脏以治疗代谢疾病的巨大潜力。

更新日期：2024-07-22

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南